| Demographics, n (%) . | Anti-TNF Naive (n = 173) . | Anti-TNF Exposed (n = 66) . | P-value . |
|---|---|---|---|
| Female | 71 (41) | 37 (56) | .04 |
| Median age at time of induction, years (IQR) | 37 (29-50) | 41 (30-49) | .56 |
| Median weight at time of escalation, kg (IQR) | 79 (65-91) | 79 (62-98) | .99 |
| Disease duration, years (IQR) | 4.0 (1.1-8.4) | 5.3 (1.3-9.0) | .38 |
| Montreal classification—age at onset | |||
| A1 < 16 years | 39 (23) | 16 (24) | .39 |
| A2—17-40 years | 114 (66) | 44 (67) | .46 |
| A3 > 40 years | 20 (11) | 6 (9) | .43 |
| Montreal classification—disease location | |||
| L1—ileal | 27 (16) | 9 (14) | .37 |
| L2—colonic | 51 (29) | 19 (29) | .49 |
| L3—ileocolonic | 92 (53) | 38 (57) | .24 |
| L4—isolated upper GI | 3 (2) | 0 (0) | .15 |
| Montreal classification—disease behavior | |||
| B1—uncomplicated | 64 (37) | 20 (30) | .25 |
| B2—stricturing | 59 (34) | 23 (35) | .42 |
| B3—penetrating | 50 (29) | 23 (35) | .18 |
| Perianal disease | 94 (54) | 38 (58) | .67 |
| Prior surgery | 81 (47) | 34 (52) | .56 |
| Current smoker | 38 (22) | 10 (15) | .28 |
| Proactive TDM | 111 (64) | 54 (82) | <.01 |
| Infliximab escalation | 95 (55) | 31 (47) | .31 |
| Adalimumab escalation | 78 (45) | 35 (53) | .31 |
| Concurrent immunomodulator use | 102 (59) | 50 (76) | .02 |
| Demographics, n (%) . | Anti-TNF Naive (n = 173) . | Anti-TNF Exposed (n = 66) . | P-value . |
|---|---|---|---|
| Female | 71 (41) | 37 (56) | .04 |
| Median age at time of induction, years (IQR) | 37 (29-50) | 41 (30-49) | .56 |
| Median weight at time of escalation, kg (IQR) | 79 (65-91) | 79 (62-98) | .99 |
| Disease duration, years (IQR) | 4.0 (1.1-8.4) | 5.3 (1.3-9.0) | .38 |
| Montreal classification—age at onset | |||
| A1 < 16 years | 39 (23) | 16 (24) | .39 |
| A2—17-40 years | 114 (66) | 44 (67) | .46 |
| A3 > 40 years | 20 (11) | 6 (9) | .43 |
| Montreal classification—disease location | |||
| L1—ileal | 27 (16) | 9 (14) | .37 |
| L2—colonic | 51 (29) | 19 (29) | .49 |
| L3—ileocolonic | 92 (53) | 38 (57) | .24 |
| L4—isolated upper GI | 3 (2) | 0 (0) | .15 |
| Montreal classification—disease behavior | |||
| B1—uncomplicated | 64 (37) | 20 (30) | .25 |
| B2—stricturing | 59 (34) | 23 (35) | .42 |
| B3—penetrating | 50 (29) | 23 (35) | .18 |
| Perianal disease | 94 (54) | 38 (58) | .67 |
| Prior surgery | 81 (47) | 34 (52) | .56 |
| Current smoker | 38 (22) | 10 (15) | .28 |
| Proactive TDM | 111 (64) | 54 (82) | <.01 |
| Infliximab escalation | 95 (55) | 31 (47) | .31 |
| Adalimumab escalation | 78 (45) | 35 (53) | .31 |
| Concurrent immunomodulator use | 102 (59) | 50 (76) | .02 |
| Demographics, n (%) . | Anti-TNF Naive (n = 173) . | Anti-TNF Exposed (n = 66) . | P-value . |
|---|---|---|---|
| Female | 71 (41) | 37 (56) | .04 |
| Median age at time of induction, years (IQR) | 37 (29-50) | 41 (30-49) | .56 |
| Median weight at time of escalation, kg (IQR) | 79 (65-91) | 79 (62-98) | .99 |
| Disease duration, years (IQR) | 4.0 (1.1-8.4) | 5.3 (1.3-9.0) | .38 |
| Montreal classification—age at onset | |||
| A1 < 16 years | 39 (23) | 16 (24) | .39 |
| A2—17-40 years | 114 (66) | 44 (67) | .46 |
| A3 > 40 years | 20 (11) | 6 (9) | .43 |
| Montreal classification—disease location | |||
| L1—ileal | 27 (16) | 9 (14) | .37 |
| L2—colonic | 51 (29) | 19 (29) | .49 |
| L3—ileocolonic | 92 (53) | 38 (57) | .24 |
| L4—isolated upper GI | 3 (2) | 0 (0) | .15 |
| Montreal classification—disease behavior | |||
| B1—uncomplicated | 64 (37) | 20 (30) | .25 |
| B2—stricturing | 59 (34) | 23 (35) | .42 |
| B3—penetrating | 50 (29) | 23 (35) | .18 |
| Perianal disease | 94 (54) | 38 (58) | .67 |
| Prior surgery | 81 (47) | 34 (52) | .56 |
| Current smoker | 38 (22) | 10 (15) | .28 |
| Proactive TDM | 111 (64) | 54 (82) | <.01 |
| Infliximab escalation | 95 (55) | 31 (47) | .31 |
| Adalimumab escalation | 78 (45) | 35 (53) | .31 |
| Concurrent immunomodulator use | 102 (59) | 50 (76) | .02 |
| Demographics, n (%) . | Anti-TNF Naive (n = 173) . | Anti-TNF Exposed (n = 66) . | P-value . |
|---|---|---|---|
| Female | 71 (41) | 37 (56) | .04 |
| Median age at time of induction, years (IQR) | 37 (29-50) | 41 (30-49) | .56 |
| Median weight at time of escalation, kg (IQR) | 79 (65-91) | 79 (62-98) | .99 |
| Disease duration, years (IQR) | 4.0 (1.1-8.4) | 5.3 (1.3-9.0) | .38 |
| Montreal classification—age at onset | |||
| A1 < 16 years | 39 (23) | 16 (24) | .39 |
| A2—17-40 years | 114 (66) | 44 (67) | .46 |
| A3 > 40 years | 20 (11) | 6 (9) | .43 |
| Montreal classification—disease location | |||
| L1—ileal | 27 (16) | 9 (14) | .37 |
| L2—colonic | 51 (29) | 19 (29) | .49 |
| L3—ileocolonic | 92 (53) | 38 (57) | .24 |
| L4—isolated upper GI | 3 (2) | 0 (0) | .15 |
| Montreal classification—disease behavior | |||
| B1—uncomplicated | 64 (37) | 20 (30) | .25 |
| B2—stricturing | 59 (34) | 23 (35) | .42 |
| B3—penetrating | 50 (29) | 23 (35) | .18 |
| Perianal disease | 94 (54) | 38 (58) | .67 |
| Prior surgery | 81 (47) | 34 (52) | .56 |
| Current smoker | 38 (22) | 10 (15) | .28 |
| Proactive TDM | 111 (64) | 54 (82) | <.01 |
| Infliximab escalation | 95 (55) | 31 (47) | .31 |
| Adalimumab escalation | 78 (45) | 35 (53) | .31 |
| Concurrent immunomodulator use | 102 (59) | 50 (76) | .02 |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
